BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

A20

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 4 :		(11) International Publication Number: WO 89/ 01340
A61K 43/00, 39/395, G01N 33/53	A1	(43) International Publication Date: 23 February 1989 (23.02.89)

(21) International Application Number: PCT/US88/02731

(22) International Filing Date: 11 August 1988 (11.08.88)

(31) Priority Application Number: 085,707

(32) Priority Date: 17 August 1987 (17.08.87)

(33) Priority Country: US

(71) Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, U.S. DEPARTMENT OF COMMERCE [US/US]; 5285 Port Royal Road, Springfield, VA 22161 (US).

(72) Inventor: WALDMANN, Thomas, A. ; 3910 Rickover Road, Silver Spring, MD 20902 (US).

(74) Agents: STERN, Marvin, R. et al.; Holman & Stern, 2401 Fifteenth Street, N.W., Washington, DC 20009 (US).

(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHOD FOR TREATING MALIGNANCY AND AUTOIMMUNE DISORDERS IN HUMANS



(57) Abstract

The present invention relates to a method for treating malignancy and autoimmune disorders and for preventing allograft rejection. Conjugated or unconjugated monoclonal anti-Tac antibodies are employed to treat the above conditions.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic			SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark	MC	Monaco	US	United States of America
FI	Finland	MG	Madagascar		

METHOD FOR TREATING MALIGNANCY AND AUTOIMMUNE DISORDERS IN HUMANS

BACKGROUND OF THE INVENTION

Technical Field:

The present invention is related to a method for treating malignancy and autoimmune disorders and for preventing allograft rejection. More particularly, the present invention is directed to treating any human condition or disorder related to the expression of Tac antigen or involving abnormal IL-2- receptor expression, by reacting Tac antigen or IL-2 receptor expressing cells with anti-Tac monoclonal antibody or a preparation thereof.

State of the Art:

The normal resting cells of the body, including T cells, do not express IL-2 receptors and thus do not react with a monoclonal antibody anti-Tac that recognizes the human IL-2 receptor. However, in certain conditions, such as in leukemic T cells of patients infected with human T-cell lymphotrophic virus I (HTLV-I-associated Adult T Cell Leukemia), large numbers of IL-2 receptors are constitutively expressed. The Tac antigen is also expressed in other malignant conditions including the malignant B lymphocytes of hairy cell leukemia,

follicular lymphoma and the Reed-Sternberg cells of Hodgkin's disease. Furthermore, activated T cells expressing the Tac antigen also appear to play a pathogenic role in certain forms of autoimmune disorders, such as type I diabetes and a subset of patients with aplastic anemia. In addition, when cells responding to foreign histocompatibility antigens become activated, they express the Tac antigen and participate in allograft rejection such as in patients receiving vascularized organ allografts and in graft-versus-host disease in patients receiving marrow allografts. Thus, there are a number of clinical circumstances where the expression of Tac-antigen is involved. Clearly, therefore, the elimination of Tac-positive cells using the anti-Tac monoclonal antibodies would be of value in treating or controlling such pathological states.

SUMMARY OF THE INVENTION

It is, therefore, an object of the present invention to provide a method of eliminating disease-associated Tac-positive cells.

It is a further object of the present invention to provide a method of treating adult T-cell leukemia or T-cell-mediated autoimmune disorders.

It is another object of the present invention to provide a method of treating B-cell malignancy.

It is yet another object of the present invention to provide a method of controlling allograft rejection reactions.

Other objects and advantages of the present invention will become apparent from the Detailed Description of the Invention.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other objects, features and many of the attendant advantages of the invention will be better understood upon a reading of the following detailed description when considered in connection with the accompanying drawings wherein:

Fig. 1 shows the results of anti-Tac therapy of patient with Tac-positive ATL. The patient was treated with four infusions (20, 40, 50, and 50 mg) of anti-Tac monoclonal antibody over a 12 day period (indicated by solid bars). After the anti-Tac therapy, the number of circulating T cells bearing the Tac antigen declined from 8000 to less than 100/mm^3. There was a parallel decline of cells expressing another tumor-associated marker of the transferrin receptor from over 9000 before therapy to less than 100/mm^3;

Fig. 2 shows the effect of anti-Tac therapy on CT β chain gene arrangement in a patient with ATL. The remission of the T-cell leukemia in this patient after anti-Tac therapy was confirmed using molecular genetic analysis of the arrangement of the genes encoding the β chain of the antigen-specific T-cell receptor. Southern analysis of the arrangement of the T-cell receptor β chain was performed on BamHI digests of DNA from the peripheral blood mononuclear cells of the patient by using a radiolabeled probe to the constant region of the T β chain. The constant T β genes are universally present on a 24-kb BamHI fragment in germline tissues of normal individuals and in a B-cell line from the patient. However, before therapy there was an additional 22-kb BamHI band hybridizing with the constant T β probe when digests of the patient's circulating T cells were examined, a hallmak of a clonal expansion of T lymphocytes. This band reflecting the clonally

rearranged T-cell receptor gene was not demonstrable on specimens obtained after anti-Tac therapy when the patient was in remission. Six months after the initial remission the leukemia recurred with reappearance of leukemic cells identified by a molecular genetic analysis. A second course of infusions of anti-Tac was followed by a virtual disappearance of the skin lesions and the circulating leukemic cells (data not shown); and

Fig. 3 shows the effect of anti-Tac therapy on leukemic mononuclear cells with integrated HTLV-I. HTLV-I is clonally integrated into the cells of patients with HTLV-I-associated ATL. Such integrated HTLV-I can be identified by Southern analysis using a radiolabeled HTLV-I probe. In the case shown, there are two lines on the Southern gel indicating the integration of two HTLV-I viruses per cell. After anti-Tac therapy, the circulating cells of this patient did not contain integrated HTLV-I as shown by the clear Southern gel radioautograph. After relaps, integrated HTLV-I could again be demonstrated in the circulation T cells.

DETAILED DESCRIPTION OF THE INVENTION

The above and various other objects and advantages of the present invention are achieved by a method of treating T-cell mediated disorders in humans comprising administering to a human afflicted with T-cell mediated discorder, therapeutic amounts of conjugated or unconjugated anti-Tac monoclonal antibodies to eliminate disease-associated Tac-positive cells without affecting normal cell populations.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art

to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference.

Prior to the present studies, little was known about the inducible IL-2 receptor, and no antibodies to IL-2 receptor had been made. Using hybridoma technology, an IgG2a mouse monoclonal antibody called anti-Tac was prepared. This anti-Tac antibody reacted with activated but not resting T cell (Uchiyama et al, J. Immunol. 126:1393-1397, 1981; Uchiyama et al, J. Immunol. 126:1398-1403, 1981). Furthermore, this antibody identified the IL-2 receptor and blocked IL-2 binding to its receptor (Leonard et al, Nature 300:267-269, 1981). The structure, function and expression of the IL-2 receptors on normal and malignant lymphocytes has been reviewed by Waldmann (Science, 232:727-732, 1986).

Based on the known unique properties of anti-Tac antibodies, a novel approach to immunotherapy was developed for the first time to eliminate leukemic cells and activated T cells in autoimmune disorders and in organ allograft protocols. These therapeutic studies were extended by coupling toxins to anti-Tac and showing that they killed tumor cells at doses that did not affect normal cells. Furthermore, anti-Tac was coupled to the alpha-emitting radionuclide such as bismuth 212 (^{212}Bi) or a β-emitting radionuclide such as yttrium-90 by the use of a bifunctional chelate. This agent was also shown to be an effective and specific immunocytotoxic agent for the elimination of IL-2 receptor-positive cells. The details of the procedure for the use of anti-Tac in the therapy of patients with adult T-cell leukemia and in organ allograft protocols are described below.

A. Treatment of ATL with Unmodified Anti-Tac

Patients with adult T-cell leukemia (ATL) are treated by intravenous infusions of unmodified anti-Tac. ATL is an aggressive leukemia of polymorphic mature T cells with a propensity to infiltrate the skin. This leukemia is frequently associated with hypercalcemia and pulmonary involvement. The leukemic cells always contain the C-type retrovirus Human T-Cell Lymphotrophic Virus I (HTLV-I). There is no curative threapy for patients with ATL, and such patients have a mean survival time of only about 20 weeks. In contrast to normal cells, the malignant cells of patients with ATL display the cell surface receptor for interleukin-2 identified by the anti-Tac monoclonal antibody.

The anti-Tac murine-derived monoclonal antibody used for these therapeutic studies has been produced by fusing NS-1 cells with spleen cells of mice immunized with a cell line derived from an ATL patient. Large quantities of the monoclonal antibody are produced by inoculating hybrid cells into the peritoneum of BALB/c mice and purifying this IgG2a κ antibody from the resulting ascites fluid by DEAE chromatography with elution by 0.1 Tris buffer as the eluting agent. The material is dialyzed against saline, centrifuged, filtered, precipitated with 20% sodium sulfate, and then diluted in saline at pH 7.4 to a concentration of about 2 mg/ml. Each lot of the product is shown to be pure by assays that include immunoelectrophoresis, diffusion in agar plates using antisera to IgG2a, IgG1, IgM, and transferrin, as well as polyvalent antibodies to major mouse proteins. Furthermore, the lots are shown to be homogenous by HPLC. The monoclonal preparations are sterilized by passge through a 0.22 millipore filter and are shown to be nonpyrogenic and sterile. Patients with Tac-expressing ATL receive anti-Tac antibody by

intravenous administration of a dose in 100 cc of normal saline with 5% human albumin over a 2-hour period.

B. Treatment of ATL with Anti-Tac Conjugated with Cytotoxic Agents

1. Anti-Tac Antibody Coupled to Ricin A Chain

Using conventional procedures, purified anti-Tac monoclonal antibody is conjugated to purified or recombinant ricin A chain using a thiol-containing crosslinker, N-succinimidyl-3-(2-pyridyldithio)propionate (Kronke et al Blood 65:1416-1421, 1985). The resulting conjugates are separated from the majority of free ricin A chains by Sephacryl S-200 gel filtration. Conjugates are adjusted to 1 mg/ml with reduced and alkylated human IgG and stored at -20°C. The addition of carrier protein assures stability of the conjugates, and the alkylation prevents disulfide toxin exchange between specific antibody and carrier protein. The addition of anti-Tac antibody coupled to the A chain of the toxin (ricin) effectively inhibited protein synthesis and led to cell death of an HTLV-I-associated, Tac-positive ATL cell line, HUT102-B2. In contrast, conjugates of ricin A with a control monoclonal of the same isotype did not inhibit protein synthesis when used in the same concentration. The inhibitory action of anti-Tac conjugated with ricin A could be abolished by the addition of excess unlabeled anti-Tac or IL-2.

2. Anti-Tac Coupled to Pseudomonas Toxin

The immunotoxin Pseudomonas exotoxin anti-tac is made from purified pyrogen-free anti-Tac and purified Pseudomonas exotoxin (PE) according to published methods (Fitsgerald et al Proc. Natl. Acad. Sci. USA 80:4134-4138, 1983). Two mg (30 nM) of PE in KPO_4 0.1 M, EGTA 1 mM, pH 8.0, is incubated with 500 nM of NAD and 5000 nM of 2-iminothiolane-HCl for 1 hour at 37°C. NAD is added to protect the enzyme-active site of the

toxin. This derivatized PE preparation is separated on HPLC from a small amount of aggregated toxin by the other reactants. Dithio-bis(2-nitrobenzoic acid) (DTNB) is added to the derivatized PE to a final concentration of about 1mM. The addition of DTNB and its reaction with free sulfhydryl groups serves to activate the toxin for future disulfide exchange with antibody.

The antibody (5-8 mg) in KPO_4 0.1 M, EGTA 1 mM, pH 8.0, is incubated with 120 nMol of 2-iminothiolane-HCL for 1 hour at 37°C. At the end of the incubation period, the antibody is separated from iminothiolane by gel filtration on a G-25 column. An aliquot of the derivatized antibody is reacted with DTNB to determine the number of new sulfhydryl groups introduced. The remainder is mixed with the activated PE. Activated PE is reacted with derivatized anti-Tac antibody. The reaction is followed by measuring the release of TNB (thionitro-benzoic acid - nitrophenol) at OD_{412}. The antibody-SH releases routinely half of the TNB from the activated PE molecules. The balance is released by adding excess cysteine. The reaction mixture is separated by HPLC. The PE-antibody-$(cys)_2$ has the most activity and is used for patient therapy. The PE-anti-Tac is stored at -20°C in 0.15 M NaCl, 10 mM KPO_4, 1 mM EGTA, pH 7.2.

Patients with ATL receive PE-anti-Tac antibody by intravenous administration in 100 cc of normal saline with 1% albumin over 2 hours. Each patient received about 200 g of PE-anti-Tac twice during the first week and 2 mg twice a week during the second week. Therapy is stopped if the patient manifests grade III hepatic toxicity, that is, a bilirubin over 3.0 mg/ml or an SGOT or alkaline phosphatase 3-5 times the base line.

Four patients have been treated with PE-anti-Tac according to this protocol. One of the four patients

manifested hepatic dysfunction, including abdominal pain and a transient disorder of the liver function tests. One of the patients had a response to the PE-anti-Tac therapy manifested by an over 50% decline in the number of circulating leukemic cells.

It is noted that other cytotoxic conjugates of anti-Tac can be similarly prepared and used. The examples provided herein being only exemplary.

C. Therapy of ATL with Anti-Tac Conjugated with Radionuclides

Anti-Tac has been successfully conjucated to the α-particle-emitting radionuclide bismuth-212 and to the β-emitting yttrium-90 by use of bifunctional ligands, such as isobutylcarboxycarbonic anhydride of diethylenetriamine-pentaacetic acid (DTPA). The physical properties of ^{212}Bi are appropriate for radioimmunotherapy in that it has a short half-life, deposits its high energy over a short distance, and can be obtained in large quantities from a radium generator. The labeling protocols have been described by Gansow et al (Am. Chem. Soc. Symp. Ser. 241:215-227). DTPA is linked to anti-Tac with ^{14}C-labeled DTPA used to identify chelate-antibody ratio. DPA (0.2 mM)was dissolved in 2 ml of H_2O by addition of triethylamine (1.38 mM) and lyophilized. The solid formed is taken up in 1 ml of acetonitrile at 4°C and treated with isobutylchloroformate (0.27 mM) for about 30 minutes, centrifuged, and a 20-µl aliquot of isobutylcarboxycarbonic anhydride solution is reacted with anti-Tac at 4°C for about 1.5 hours. Sequential dialyses in metal-free buffer are used to purify the protein. A comparable procedure is used to couple anti-Tac to the β-emitting radionuclide yttrium-90. Conjugates with other α or β emitting nuclides are

similarly prepared and used. The examples provided herein being only exemplary.

Activity levels of 0.5 μCi or the equivalent of 12 rad/ml of α irradiation targeted by ^{212}Bi-anti-Tac eliminated more than 98% of the proliferative capacity of the HUT102-B2 cells with only minimal effect on IL-2 receptor-negative lines. This specific cytotoxicity was blocked by excess unlabeled anti-Tac but not by human IgG. Thus, ^{212}Bi-anti-Tac is an effective and specific immunocytotoxic agent for the elimination of IL-2 receptor-positive ATL cells.

D. Protocol for Treatment of Autoimmune Disorders

Patients with certain forms of autoimmune disease, including subsets of patients with the disease aplastic anemia, have increased number of circulating and marrow Tac-positive T cells. In this group of patients, the Tac-positive but not the Tac-negative T cells inhibit hematopoiesis when cocultured with normal bone marrow cells. Patients with elevated number of Tac-positive T cells and associated aplastic anemia receive unmodified anti-Tac monoclonal antibody in 100 ml normal saline with 5% alumin by intravenous administration over a 2 hour period. Patients are treated with 20 mg of anti-Tac three times over a 7 to 10 day period. This course may be modified and repeated if Tac positive cells remain elevated.

An alternative therapeutic approach with anti-Tac is the use of Pseudomonas exotoxin anti-Tac according to protocols described above. Patients receive about 200 ug of PE-anti-Tac twice a week during the first week of treatment and at doses of about 2 mg twice a week during the second week.

E. Protocol for Treatment to Prevent Allograft Rejection

After renal or cardiac allografts and during graft-versus-host diesase, certain host T lymphocytes recognize the foreign histocompatibility antigens expressed on the donor organs and thus become activated and express the Tac antigen. Such Tac-expressing activated T cells participate in the rejection of the allografts and in the graft-versus-host disease. The survival of renal allografts was prolonged in cynomolgus monkey recipients treated with the anti-Tac monoclonal antibody.

In patient studies, intravenously administered anti-Tac is added to conventional immunosuppression to prevent allograft rejection. The patients receive anti-Tac monoclonal antibody by intravenous adminstration in 100 ml of glucose or saline with 5% albumin carrier over about 2 hours. The patients are treated with about 20 mg of anti-Tac daily for about 10 days between the first and tenth day after their receipt of the organ allograft.

Eight patients receiving renal allografts have been treated with the above protocol of anti-Tac in addition to conventional immunsupression. None of these patients manifested toxicity due to the anti-Tac monoclonal antibody. Furthermore, none of them have rejected the transplanted kidney.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

WHAT IS CLAIMED IS

1. A method of treating T-cell mediated disorders in humans, comprising administering to a human afflicted with T-cell mediated disorder, therapeutic amount of conjugated or unconjugated anti-Tac monoclonal antibody to eliminate disease-associated Tac-positive cells without affecting normal cells.

2. The method of claim 1 wherein T-cell mediated disorder is Adult-T-Cell Leukemia, autoimmune disfunction, or allograft incompatibility.

3. The method of claim 2 wherein said disorder is Adult T-Cell Leukemia.

4. The method of claim 1 wherein said disorder is autoimmune disfunction.

5. The method of claim 2 wherein said disorder is allograft incompatability.

6. The method of claim 1 wherein said anti-Tac monoclonal antibody is conjugated with a cytotoxic agent.

7. The method of claim 6 wherein said cytotoxic agent is selected from the group consisting of toxin and radionuclide.

8. The method of claim 7, wherein said toxin is selected from the group consiting of ricin-A and pseudomonas toxin.

9. The method of claim 8 wherein said toxin is ricin-A.

10. The method of claim 8 wherein said toxin is pseudomonas toxin.

11. The method of claim 7 wherein said radionuclide is alpha-emitting or beta-emitting radionuclide.

12. The method of claim 11, wherein said alpha-emitting radionuclid is ^{212}Bi.

13. The method of claim 11, wherein said beta-emitting radionuclide is yttrium-90.

FIG. 1


10,000
8,000
6,000
4,000
2,000
Cells/mm3
Tac + cells
Transferrin receptor + cells
mg
60
40
20
Anti-Tac
0
5
10
15
20
Days

FIG. 2


Normal
Patient Relapse 3/84 6/84
Patient Remission 7/84
Patient Relapse 8/84
Patient B Cells


Patient Relapse 7/83
6/84
Patient Remission 7/84
Patient Relapse 9/84
Eco RI

FIG. 3

INTERNATIONAL SEARCH REPORT

International Application No PCT/US88/02731

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) [3]

According to International Patent Classification (IPC) or to both National Classification and IPC

INT. CL. [4] A61K 43/00; A61K 39/395; G01N 33/53

U.S. CL. 424/1.1; 424/85; 436/548

II. FIELDS SEARCHED

Minimum Documentation Searched [4]

Classification System	Classification Symbols
U.S.	424/1.1, 9, 85 436/547,548

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched [5]

III. DOCUMENTS CONSIDERED TO BE RELEVANT [14]

Category *	Citation of Document, [16] with indication, where appropriate, of the relevant passages [17]	Relevant to Claim No. [18]
X Y	PROCEEDINGS OF NATIONAL ACADEMY OF SCIENCE, VOLUME 83, 1986 JANUARY, R.W. KOZAK ET AL., 'BISMUTH-212-LABELED ANTI-TAC MONOCLONAL ANTIBODY', (SEE PAGES 474, 477, 478).	1-8, 10-12 9, 13
Y	THE JOURNAL OF CLINICAL INVESTIGATION, VOLUME 74, 1984 SEPTEMBER, D.J.P. FITZGERALD ET AL, 'PSEUDOMONAS EXOTOXIN-ANTI-TAC', (SEE PAGE 967).	8, 10
Y	BLOOD, VOLUME 65, NO. 6, 1985 JUNE, M. KRONKE ET AL., 'ADULT T CELL LEUKEMIA', (SEE PAGE 1417).	8, 9
Y	DE,A, 2,011,612, INSTITUTE MEDITSKINSKOI RADIOLOGII 30 SEPTEMBER 1971, (SEE THE ENGLISH ABSTRACT).	13
Y	SU,A, 438419, BIOPHYSICS INSTITUTE, 29 JANUARY 1975, (SEE THE ENGLISH ABSTRACT).	13

* Special categories of cited documents: [15]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search [2]	Date of Mailing of this International Search Report [2]
23 NOVEMBER 1988	11 JAN 1989
International Searching Authority [1]	**Signature of Authorized Officer [20]**
ISA/US	JOHN S. MAPLES John S Maples

Form PCT/ISA/210 (second sheet) (May 1986)